The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013585" target="_blank" >RIV/00023736:_____/24:00013585 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00135451 RIV/65269705:_____/24:00078546 RIV/00179906:_____/24:10481286 RIV/00098892:_____/24:10158181

Výsledek na webu

<a href="https://doi.org/10.1080/10428194.2023.2280886" target="_blank" >https://doi.org/10.1080/10428194.2023.2280886</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2023.2280886" target="_blank" >10.1080/10428194.2023.2280886</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Popis výsledku v původním jazyce

Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.

Název v anglickém jazyce

The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Popis výsledku anglicky

Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia & lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

65

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

199-208

Kód UT WoS článku

001103157000001

EID výsledku v databázi Scopus

2-s2.0-85176920648